Your session is about to expire
← Back to Search
Long-Term Apremilast Use for Psoriasis
Study Summary
This trial provides the option to continue apremilast treatment for up to 4 years for those who complete an initial 52-week trial. There will be an 8-week observational follow-up phase.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 4 trial • 20 Patients • NCT03000309Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the target number of enrollees for this trial?
"In order to carry out this investigation, 140 individuals that meet the prerequisites will be needed. The sponsor, Amgen, will be conducting the trial from various locations, including Solutions Through Advanced Research Inc in Jacksonville, Florida and Johnson Dermatology Clinic in Fort Smith, Arkansas."
Are individuals who are younger than 55 years old allowed to participate in this research project?
"In order to meet the requirements to participate in this clinical trial, applicants must be between the ages of 6 and 17. Out of the 200 total clinical trials, 36 are for patients that are under 18 years old and 164 are for patients that are over 65 years old."
Which patients does this research require?
"This clinical trial is looking for 140 children and adolescents aged 6 to 17 with psoriasis. The following inclusion criteria must be met:- The subject must have a weight of ≥ 20 kg.- The subject must have completed Week 52 (Apremilast Extension Phase) of Study CC-10004-PPSO-003.- The subject is willing and able to adhere to the study visit schedule and other protocol requirements.- The subject's age and sex specific BMI value must be no lower in range than the 5th percentile on the Centers for Disease Control (CDC) growth chart."
What is the precedent for using Apremilast in medical treatment?
"Attikon Hospital was the first to study apremilast back in 2014. So far, a total of 76 clinical trials have been completed with 14 more currently underway. These active studies are primarily based in Jacksonville, Florida."
Could you please tell us about Apremilast's safety records?
"There is some evidence indicating that Apremilast is effective, and multiple clinical trials have supported its safety, so it received a score of 3."
What are the primary conditions that Apremilast treats?
"Apremilast is not only effective in the treatment of ulcers, but also for other chronic inflammatory diseases like psoriasis, behcet's syndrome, and severe plaque psoriasis."
Could you please provide the total number of hospitals currently participating in this trial?
"Solutions Through Advanced Research Inc in Jacksonville, Florida, Johnson Dermatology Clinic in Fort Smith, Arkansas, Skin care Physicians of Georgia in Macon, Georgia, and 17 other locations are where this research is being conducted."
Who else is applying?
How old are they?
What portion of applicants met pre-screening criteria?
What state do they live in?
What site did they apply to?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger